Targeting the virus with radioimmunotherapy in virus-associated cancers

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 3, 2007, Pages 303-308

  Dadachova, Ekaterina ^a   Wang, Xing Guo ^a,b   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HUBEI UNIVERSITY   (China)

Author keywords

Radioimmunotherapy; Viral infection; Virus associated cancer

Indexed keywords

ASTATINE 211; BISMUTH 212; BISMUTH 213; BROMINE 76; CD20 ANTIGEN; FERMIUM; FLUORINE 18; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; IBRITUMOMAB TIUXETAN; LEAD 212; LUTETIUM 177; MONOCLONAL ANTIBODY; PROTEIN E6; PROTEIN E7; RADON; RADON 223; RADON 224; RADON 225; RHENIUM 188; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS GLYCOPROTEIN; YTTRIUM 90;

BREAST CANCER; CANCER IMMUNOTHERAPY; DRUG TARGETING; EPSTEIN BARR VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIVER CELL CARCINOMA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; NASOPHARYNX CANCER; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; VIRUS INFECTION; WART VIRUS;

HUMANS; NEOPLASMS; RADIOIMMUNOTHERAPY; VIRUS DISEASES;

EID: 34447503809     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.344     Document Type: Review

References (26)

1. Cesarman E, Mesri EA. Kaposi sarcoma-associated herpesvirus and other viruses in human lymphomagenesis. Curr Top Microbiol Immunol 2007;312:263.
2. Jones EE, Wells SI. Cervical cancer and human papillomaviruses: inactivation of retinoblastoma and other tumor suppressor pathways. Curr Mol Med 2006; 6:795.
3. El-Aneed A, Banoub J. Proteomics in the diagnosis of hepatocellular carcinoma: Focus on high-risk hepatitis B and C patients. Anticancer Res 2006;26:3293.
4. Arbach H, Viglasky V, Lefeu F, et al. Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: Effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol). J Virol 2006;80:845.
5. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: From latent genes to tumours. Oncogene 2003; 22:5108.
6. Mortreux F, Gabet A-S, Wattel E. Molecular and cellular aspects of HTLV-1-associated leukemogenesis in vivo. Leukemia 2003;17:26.
7. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74.
8. Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22,707 men in Taiwan. Lancet 1981;2:1129.
9. Order S, Stillwagon GB, Klein JL, et al. Iodine 131-antiferritin, a new treatment modality in hepatoma: A Radiation Oncology Group study. J Clin Oncol 1985;3: 1573.
10. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005;46(Suppl 1):115S.
11. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 2004;3:488.
12. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441.
13. Dadachova E, Casadevall A. Treatment of infection with radiolabeled antibodies. Q J Nucl Med Mol Imag 2006;50:193.
14. Dadachova E, Patel MC, Toussi S, et al. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med 2006;3:e427.
15. Casadevall A, Goldstein H, Dadachova E. Targeting viruses-harboring host cells with radiolabeled antibodies. Exp Opin Biol Ther 2007;7:595.
16. 131I-labeled TNT-1 monoclonal antibody. Cancer Res 1989;49:4578.
17. Krishnamurthy S, Takimoto T, Scroggs RA, et al. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 2006;80:5145.
18. Zárate S, Novella IS. Vesicular stomatitis virus evolution during alternation between persistent infection in insect cells and acute infection in mammalian cells is dominated by the persistence phase. J Virol 2004;78:12236.
19. Fernandez M, Porosnicu M, Markovic D, et al. Genetically engineered vesicular stomatitis virus in gene therapy: Application for treatment of malignant disease. J Virol 2002;76:895.
20. Dadachova E, Casadevall A. Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases. Exp Opin Drug Deliv 2005;2:1075.
21. Dadachova E, Nosanchuk JD, Shi L, et al. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a monoclonal antibody to melanin. Proc Natl Acad Sci USA 2004;101:14865.
22. Dadachova E, Moadel T, Schweitzer AD, et al. Radio-labeled melanin-binding peptides are safe and effective in treatment of human pigmented melanoma in a mouse model of disease. Cancer Biother Radiopharm 2006;21: 117.
23. Knox SJ, Meredith R. Clinical radioimmunotherapy. Semin Radiat Oncol 2000;10:73.
24. 90Y ibritumomab tiuxetan (Zevalin). Semin Oncol 2003;30(6 Suppl. 17):6.
25. Drake JW. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci USA 1993;90:4171.
26. Hall E. Hereditary effects of radiation. In: Radiobiology for the Radiologist, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2000.